In the 1980s, Elliot and colleagues argued that urothelial damage could occur after washouts and irrigations of the bladder. The authors measured the rate of exfoliation of urothelial cells ...

Trodelvy carries a boxed warning for neutropenia, a common condition among people receiving cancer treatments that results in lower-than-normal levels of a type of white blood cells. Bladder ...

After falling short in a confirmatory clinical trial, Gilead Sciences has decided to withdraw Trodelvy as a bladder cancer treatment in the U.S. The California biotech announced the decision ...

The move is a blow to Gilead’s cancer portfolio. Trodelvy, an antibody-drug conjugate granted accelerated approval for bladder cancer in 2021, failed its confirmatory trial earlier this year. Gilead ...